Department of Public Health, Epidemiology and Health Economics, University of Liège, Avenue de l'Hôpital 3 - CHU B23, Liège, 4000 Belgium ; Support Unit in Epidemiology and Biostatistics, University of Liège, Liège, Belgium.
Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle Perret-Gentil 4, Geneva 14, CH-1211 Switzerland.
Arch Public Health. 2014 Dec 18;72(1):45. doi: 10.1186/2049-3258-72-45. eCollection 2014.
Sarcopenia, operationally defined as the loss of muscle mass and muscle function, is a major health condition associated with ageing, and contributes to many components of public health at both the patient and the societal levels. Currently, no consensual definition of sarcopenia exists and therefore it is still a challenge to establish the actual prevalence of sarcopenia or to establish the direct and indirect impacts of sarcopenia on public health. Anyway, this geriatric syndrome represents a huge potential public health issue because of its multiple clinical and societal consequences. Moreover, all these aspects have an impact on healthcare costs both for the patient and the society. Therefore, the implementation of effective and broadly applicable preventive and therapeutic interventions has become a medical and societal challenge for the growing number of older persons affected by sarcopenia and its disabling complications.
肌少症,临床上定义为肌肉质量和肌肉功能的丧失,是与衰老相关的主要健康问题,对患者和社会层面的许多公共卫生问题都有影响。目前,肌少症尚无公认的定义,因此,要确定肌少症的实际患病率,或确定肌少症对公共卫生的直接和间接影响,仍然具有挑战性。无论如何,这种老年综合征代表了一个巨大的潜在公共卫生问题,因为它有多种临床和社会后果。此外,所有这些方面都会对患者和社会的医疗保健成本产生影响。因此,对于越来越多受肌少症及其致残并发症影响的老年人来说,实施有效且广泛适用的预防和治疗干预措施已成为医学和社会的挑战。